How Blast Crisis Medications Work

Blast crisis is a severe and life-threatening complication of chronic myeloid leukemia (CML). It occurs when the disease progresses to an accelerated phase, characterized by an increase in blast cells in the bone marrow. In this phase, the cancer becomes more aggressive and resistant to treatment.

Gold Standard Treatment: Imatinib

The gold standard treatment for blast crisis is Imatinib, a tyrosine kinase inhibitor (TKI). Imatinib works by targeting and inhibiting the BCR-ABL1 protein, which is responsible for the proliferation of cancer cells in CML. By blocking this protein, Imatinib reduces the growth and survival of cancer cells, leading to improved outcomes.

Alternative Treatments

• Dasatinib: Another TKI that targets BCR-ABL1, offering an alternative for patients who are resistant or intolerant to Imatinib.

• Nilotinib: A third TKI that also targets BCR-ABL1, providing a treatment option for patients who have failed Imatinib or Dasatinib.

• Busulfan: An alkylating agent used as a last resort in blast crisis, which works by damaging the DNA of cancer cells and preventing their growth.

It's essential to note that treatment choice depends on individual patient factors, such as previous treatment history, age, performance status, and presence of BCR-ABL1 mutation. A thorough evaluation and discussion with a healthcare provider are necessary to determine the most appropriate course of treatment for each patient.